Zealand Pharma A/S (CPH:ZEAL)

Market Cap	29.59B -39.8%
Revenue (ttm)	9.16B +11,809.7%
Net Income	6.54B
EPS	91.63
Shares Out	70.44M
PE Ratio	4.58
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	309,043
Average Volume	374,707
Open	409.60
Previous Close	411.90
Day's Range	409.00 - 430.70
52-Week Range	306.10 - 788.00
Beta	0.56
RSI	44.64
Earnings Date	Feb 19, 2026

About Zealand Pharma

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 440
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: ZEAL

Financial Performance

In 2024, Zealand Pharma's revenue was 62.69 million, a decrease of -81.71% compared to the previous year's 342.79 million. Losses were -1.08 billion, 53.3% more than in 2023.